The Use of Monoclonal Antibodies in Treatment of Alzheimer Disease

Hemen Moradi-Sardareh¹, Maryam Moradi², Elham Bordbar³, Mohammadreza Malekpour⁴, Sara Bagheri⁵, Nasrin Nakhodazadeh⁶, Shahin Rahbar⁷, Javad Farhadian Asgarabadi⁸

¹Department of Clinical Biochemistry, Medical School, Tehran University of Medical Sciences, Tehran, Iran. ²Department of Immunology and Hematology, Faculty of Medicine, Kurdistan University Of Medical Sciences, Sanandaj, Iran. ³Departments of Sciences, Faculty of Biochemistry, East Tehran Branch, Payame Noor University (PNU), Tehran, Iran. ⁴Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. ⁵Department of Clinical Biochemistry, Medical School, Hamadan University of Medical Sciences, Hamadan, Iran. ⁶In One of Laboratory Located on Southeast at Tehran Town. ⁷Institute of Medical History Studies, Islamic And Complementary Medicine, Iran University of Medical Sciences. ⁸Expert of Public Health, Shahroud University of Medical Sciences, Iran.

Abstract

Background and objective: Antibody molecules have similar structure but variable binding sites to antigen. Human antibodies are achieved by transgenic mouse technology or phage display. Antibodies are used for the treatment of different diseases. Alzheimer is a cow disease with a delayed onset overpresenting in adults in their 70s to 90s. This disease is the leading cause of central nervous system (CNS) degeneration during 7 to 15 years in the aging population. Several hypotheses have offered monoclonal antibodies action mechanism in relation to amyloid cleaning at Alzheimer disease. According to this mechanism, the appropriate antibody passes blood-brain barrier, enters into brain, and binds to amyloid to launch its phagocytosis activity in microglia and/or macrophage/monocytes infiltrating. The present study aimed to review antibody structure and the use of different antibodies for the treatment of Alzheimer disease.

Keywords: Alzheimer disease- antibody- Crenezumab- Solanezumab

Introduction

Antibody structure

Although antibody molecules have similar structure, they have different antigen-binding sites. Practical activities and normal chemical and physical features of antibodies are related to some antibodies regions which are called Fc regions (antigen does not usually connect to these regions and has low variety in antibody treasure). Each antibody molecule is consisted of two identical light and two identical heavy chains. Both heavy and light chains are composed of structural domains called immunoglobulin domains, having about 70–110 amino acids. Each chain is independently folded with a sphere-shaped pattern and Each domain is constructed from two β sheets which are elements of protein structure made up of strands of the polypeptide chain (β strands) packed together.

Heavy and light chains have variable regions in their N–terminal, contributing to antigen recognition but include constant regions in their C-terminal which play role in their practical activities. Each of variable or constant regions has only one domain immunoglobulin in light chains. Variable regions have different amino acid sequences in different antibody which are good indicators for produced antibodies diagnosis of different clones. Heavy chain variable region (VH) is placed in vicinity of the light chain variable region (VL) and forms the binding site to antigen together [1-3]. Antibody structure is presented in Figure 1.

1- Monoclonal antibody with murine origin is achieved through hybridomas technology. This antibody creates sensitive responses; it has a short half-life, and has poor durable effects.

Corresponding Author:
Dr. Hemen Moradi-Sardareh
Department of Clinical Biochemistry, Medical School, Tehran University of Medical Sciences, Tehran, Iran.
Email: hemen.moradi@yahoo.com
Alzheimer disease (AD)

Alzheimer is a cow disease with a delayed onset overpresenting in adults in their 70s to 90s. This disease is the leading cause of central nervous system (CNS) degeneration during 7 to 15 years in the aging population. About 4 million Americans were intensively involved with AD and the amount of money that was directly spent on this disease was about 100 billion dollars in addition to financial burden imposed by indirect costs. It has been estimated that by a 5-year delay in the onset of Alzheimer saves about 50 billion dollars in the medical section [9].

Alois Alzheimer, a German psychiatrist and neuropathologist, introduced AD at 1906; the first symptoms observed by this scientist was pathological feature, including abnormal plaque of beta-amyloid protein (extracellular particle containing beta-amyloid) and neurofibrillar skeins (intracellular particle containing tau protein) in patient’s brain pathology that was associated with verbal and behavioral disorders [10]. Since then, AD has become one of the most prevalent disorders in the elderly people so that it has allocated to itself the sixth leading cause of death and the fifth leading cause of death in people over 65 in America [10].

The inherited Alzheimer is associated with mutation in Amyloid Precursor Protein (APP) encoding gene [11], which is located on chromosome 21 [12]. Mutation in presenilin-1 gene, which is an important gene in determining gamma secretase activity for beta amyloid production, can cause acceleration in early Alzheimer [13]. APO E4 gene locating on chromosome 14 is indirectly related to AD [14]. Mutations lead to an early onset of AD as dominant autosomal.

Some hypotheses have been proposed for AD. To manage this disease, its mechanism should be clarified first.

Cholinergic hypthesis

AD Cholinergic hypothesis was dominant about 2 decades before. At AD, Acetyl choline is decreased in the cerebral cortex and hippocampus which can be due to sharp drop of acetyl choline transferase enzyme [18]. The brain’s hippocampus, the main area involved in the processing of memory, is under the influence of cholinergic modulation [19]. One of the identified abnormalities is dependent on changes in neurotransmitter nerves, the destruction of cholinergic neurons, and the loss of cholinergic intakes to neocortex and hippocampus. Several studies have shown a reduction in nicotine and muscarinic receptors in the cortex and hippocampus of patients with AD [20].

Dendrite hypothesis

Dendritic abnormalities occur in the early stages of AD [21]. Amyloid-beta peptide (Aβ) soluble oligomers are reported to be responsible for major dendritic pathologies that can trigger the activation of the N-methyl-D-aspartate (NMDAR) receptor by forming complexes with normal cell-surface prion protein (PrPC). The Prion proteins in neural synapses can interact with the Fyn tyrosine kinase-the metabotropic glutamate receptor complex. When Aβ is attached to the MGlurR5-Fyn-PrPC-complex, the Fyn kinase protein is activated and subsequently phosphorylates the tyrosine residue of NR2B subunit from the NMDAR and plays a significant role in advancing other signaling steps in the pathology of AD [22]. Two antibodies of Saracatinib and Masitinib are Fyn inhibitors, both of which are capable of blocking Fyn. Masitinib can also inhibit inflammation of the nerve tissue by inhibiting the SCF/c-Kit signaling on mast cells by blocking the interactions between microglia-activated mast cells [23].
Figure 1. Antibody General Structure

Table 1. Naming Manner of Different Monoclonal Antibody

<table>
<thead>
<tr>
<th>Kind</th>
<th>Source</th>
<th>Suffix</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>an antibody that completely derived from mouse</td>
<td>-Omob</td>
<td>edrecolomab</td>
</tr>
<tr>
<td>Chimeric</td>
<td>an antibody that contains mouse binding site and human Fc part</td>
<td>-ximab</td>
<td>Infliximab</td>
</tr>
<tr>
<td>Humanized</td>
<td>only include mouse CDR regions</td>
<td>-zumab</td>
<td>daclizumab</td>
</tr>
<tr>
<td>Human</td>
<td>an antibody that completely derived from human source</td>
<td>-umab</td>
<td>adalimumab</td>
</tr>
</tbody>
</table>

Amyloid cascade hypothesis

This newer hypothesis about AD is based on disease pathological features. All Alzheimer patients, according to definition, have extracellular amyloid deposits that originally include Aβ.

Amyloid plaques have been considered as a vital stage in disease pathogenesis in genetic mutations studies [24]. Amyloid cascade hypothesis offers that peptide 42 production is increased of amyloid β amino acids (Aβ42) or its decomposition reduction and also its accumulation leads to synaptic changes and Aβ42 deposits at published plaques which this state is led to microglia and astrocytes activation. In active vaccination against Aβ42, which patients with AD receive the antigen itself but in passive vaccination, peoples receive monoclonal antibodies against Aβ42. Thereupon, neuronal homeostasis change, and oxidative damage lead to formation of such skeins that finally cause synaptic and neuronal function disorders and neurons selective loss [25, 26]. This hypothesis has provided essential foundations for making new drugs.

The final reason for popularity of this hypothesis is that this intervention in cascade can prevent mental destruction by genetic engineering methods [4].

and neuron loss. Aβ peptide is a 40 to 42 amino acid piece which is created by a larger protein, APP. This peptide is produced by 2-β seretase (n-terminal cutter) and γ secretase (C-terminal cutter) enzymes as APP productive slight product [25]. APP general structure is shown in Figure 3.

3 forms of AB will be free according to cut-off point by γ-secretase

A: amino acid 38, B: amino acid 40, C: amino acid 42

Aβ42 is more talented than AB40 peptide for aligomersation and amyloid fibrillar forms formation in which it is abundantly produced. Aβoligomers will apply their harmful effects through their direct connection to the neurons membrane or specific receptors needed for messaging [27-29].

APP is first broken by β-seretase which is an aspartyl protease (that is also called β-amyloid separator enzyme) in Aβ n-terminal domain and causes large actodomain pouring into extracellular fluid and duct and also leaves...
It has been offered that Aβ accumulation in the extracellular space is responsible for neurons cytotoxic effects and it has been determined during the past decade that profibrillar forms and Aβ solution are also pathogen that can damage synapses and neurons.

Therapeutic intervention strategies with Aβ target

There are 3 therapeutic intervention strategies with Aβ target right now, including the decreased Aβ production, Aβ cleaning facilitates, and prevention of Aβ accumulation.

These strategies have been tested in clinical trials. Adjustment of γ and β secretase is important for decreased AB production, passive immunization by monoclonal antibody and active immunization to stimulate Aβ cleaning, and finally preventing of Aβ accumulation with β-sheet shear enzymes and pathological chaperone inhibitors [30].

The designed monoclonal antibodies for AD treatment are from both humanized and human complete monoclonal antibody.

Several hypotheses have offered monoclonal antibodies action mechanism in relation to amyloid cleaning at AD [31]. The first offered mechanism is that the antibody bonding to amyloid leads to macrophage phagocytosis and complement activation [32]. Accordingly, it is assumed that the appropriate antibody passes of blood-brain barrier, enters into brain, and binds to amyloid to launch this phagocytosis activity in microglia and/or macrophage/monocytes infiltrating. The second offered mechanism is called peripheral sink where the amyloid balance in the blood-brain barrier is changed to its outside and leads to reduction of free Aβ concentration in blood.

A new approach for AD treatment by mabs is passive immunization against pyroglutamate-3 Aβ. Pyroglutamate-3 Aβ resists against decomposition (it is neurotoxic) and may be act as Aβ accumulation initiator. In pre-clinical trials, passive immunization with Aβ monoclonal antibodies of pyroglutamate-3 reduces plaque deposits [33-34].

Antibodies as the potential therapeutic agents in Alzheimer disease

The use of antibodies for Alzheimer disease treatment was initiated for the first time when antibodies raised against Aβ peptide pieces in vitro for blocking amyloid fibrils formation of Aβ [26]. Some specific functions of antibodies epitopes have been even determined and observed that antibodies against amino acids 1 to 28 were more effective for blocking fibrinogens while the antibodies against amino acids 8 to 17 were not influential [26].

Antibodies against peptide n-terminal parts are active (amino acids 1 to 16) while other antibodies against other parts are not effective (amino acids 13 to 28, amino acids 33 to 40) [35].

In 2001, it was showed that peripheral injection of anti-Aβ monoclonal antibodies with high affinity led to remarkable increase of Aβ in plasma and repetition of

Table 1. The Designed Monoclonal Antibodies for Alzheimer Disease

<table>
<thead>
<tr>
<th>Name</th>
<th>Kind</th>
<th>Epitope</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bapineuzumab</td>
<td>humanized</td>
<td>N-terminal</td>
</tr>
<tr>
<td>Solanezumab</td>
<td>humanized</td>
<td>Central part (amino acids 16 to 24)</td>
</tr>
<tr>
<td>Gantenerumab</td>
<td>human</td>
<td>AB central part and n-terminal</td>
</tr>
<tr>
<td>Crenezumab</td>
<td>humanized</td>
<td>Conformation epitope including oligomeric forms and AB proto-fibrillar</td>
</tr>
<tr>
<td>BAN2401</td>
<td>Humanized</td>
<td>AB proto-fibrillars</td>
</tr>
<tr>
<td>GSK 933776</td>
<td>IgG1</td>
<td>N-terminal</td>
</tr>
<tr>
<td>AAB-003</td>
<td>Fc-engineered</td>
<td>N-terminal</td>
</tr>
<tr>
<td>SAR228810</td>
<td>humanized</td>
<td>Proto-fibrillars and ABs with low molecular weight</td>
</tr>
<tr>
<td>BIIB037/BART</td>
<td>Human</td>
<td>insoluble fibrillar human AB</td>
</tr>
</tbody>
</table>

a carboxyl terminal membrane piece that has 99 amino acids. This long piece will be subsequently broken by γ-secretase and Aβ is released [27-29]. Shear secretase enzymes of APP is shown in Figure 4.

The most APP shear production in Aβ16 amino acid is created by -secretase (90%) that prevents Aβ peptide formation. The available documents suggest that carboxyl terminal shear by γ-secretase can be created in amino acid 40 and/or 42. In natural conditions, Aβ which is built in CNS has half-life clearing of 1-2 hours [25].

Figure 4. Shear Secretase Enzymes of Amyloid Precursor Protein. In effect of -α secretase enzyme an amino acid 83 piece will remain in membrane that is subsequently cut by γ-secretase; this direction cannot produce amyloid plaques. In next direction first amyloid precursor protein is cut by β-secretase and a 99 amino acid carboxyl terminal piece remains in membrane, then it is cut by γ-secretase and produces 40 and 42 amyloid amino acid pieces that can form amyloid plaques.
injections was associated with noticeable reduction of amyloid burden in vivo [36]. It was reported that only 25% of Alzheimer’s disease patients treated with AN1792 had an anti-Aβ antibody response and indicated that antibody responders scored significantly better in composite scores of memory functions than nonresponders or placebo-treated patients [37]. Anti-Aβ antibodies can even solve pre-existing fibrils and prevent Aβ fibrils neuronal toxicity [38].

Demattos et al [39] were unable in identifying and finding anti Aβ antibodies in brain and argued that circulating antibodies acted as a pit or sink for Aβ and changed Aβ balance between brain and blood toward its distribution in blood. These authors found that the initial speed that Aβ accumulates in blood after anti Aβ antibody injection was highly correlated with the amount of amyloid burden in brain.

Alzheimer's disease immunotherapy

Different approaches have been proposed for the treatment of AD, among which vaccination and immunotherapy are the most popular ones. Immunotherapy in AD includes 2 types of vaccinations: active vaccination against Aβ42 in which patients receive antigens and inactive vaccinations, in which patients are given anti-Aβ monoclonal antibodies [40].

Anti-amyloid active immunotherapy

It was reported in the mid 1990s that anti-Aβ monoclonal antibodies can be used to prevent the formation of fiber Aβ and decomposition of prefabricated fibers and plaques [26]. These antibodies decrease the levels of Aβ in the brain and also improve memory performance [41]. Due to potentially dangerous autoimmune/inflammatory reactions from recently activated inflammatory T cells, new peptide vaccines have been designed in which the T cell activation sequences are eliminated and only fragments for the production of specific antibodies against Aβ remains. Three types of peptide vaccines for active immunization are CAD106, ACC001, and Affitope. The use of these vaccines reveals specific antibody reactions that have no symptoms of autoimmune inflammation. Various experiments have shown that CAD106 has favorable immune characteristics and adequate antibody response in AD patients. The ACImmune-35 vaccine (ACI-35) is designed to stimulate the production of antibodies that target tau protein in the brain [42-43].

Inactive anti-amyloid immunotherapy

Another approach is the use of human monoclonal antibodies, which are injected as inactive immunotherapy. Inactive anti-amyloid immunotherapy is an intravenous injection of anti-Aβ monoclonal or polyclonal antibodies to the patient. In vivo studies have suggested that inactive immunization reduces the amount of brain amyloid. This can contribute to the neutralization of soluble amyloid oligomers that are increasingly precipitated and play an important role in the AD pathophysiology [16]. An overview of the used monoclonal antibodies for Alzheimer disease is shown in Table 1.

Monoclonal antibodies Bapineuzumab

Bapineuzumab is a humanized monoclonal antibody that acts against AB n-terminal [44]. Treatment with this monoclonal antibody reduces the amount of fibrillar amyloid burden in Alzheimer patients [45]. Bapineuzumab significantly reduces cerebral amyloid plaques and Tau phosphorylation in the cerebrospinal fluid [46].

Solanezumab

Solanezumab is a humanized monoclonal antibody that acts against central part of AB solution. This antibody prescription is highly tolerable; treatment with this antibody is correlated with dose-dependent increase in disconnected amyloid CSF (1-42), suggesting that its balance is changed from amyloid plaque form to amyloid (1-42) [47]. Solanezumab is used in AD patients and in elderly people who have normal memory thinking and function but may be at increased risk of AD in the future [46].

Gantenerumab

Gantenerumab is a human complete IgG1 monoclonal antibody that acts against both n-terminals and AB middle parts and is designed to bind to epitopes of beta-amyloid fibers with high affinity, which is used in individuals at high risk of developing advanced AD presenile due to genetic mutations [48]. Treatment of patients with mild to moderate Alzheimer by this antibody leads to significant decrease at AB levels in brain [47].

Crenezumab

Crenezumab is a humanized monoclonal antibody that acts against monomeric forms and conformation epitopes which includes oligomeric forms and AB proto-fibrillar [49-51].

Solanezumab

Solanezumab is an anti-Aβ monoclonal antibody which has promoted Phase III clinical trials, directed against the Aβ13–28 area and able to determine various N-terminal truncated species such as Aβ3–42 which are found in Alzheimer’s disease senile plaques [52]. The recent failure of γ-secretase in inhibiting semagacestat, avagacestat, and monoclonal antibody bapineuzumab and the lack of highlighted beneficial impacts for solanezumab offer the re-examination of earlier intervention.

Ponezumab

Ponezumab is one of the other monoclonal anti-Aβ antibodies targeting the amino acids 33-40 of the Aβ peptide [40].

MABT5102A

MABT5102A is associated with Aβ monomers, Oligomers, and fibrils with high ratios [40].

BAN2401

BAN2401 is a humanized immunoglobulin G1 monoclonal antibody (IgG1) that is selectively bond to AB proto-fibrillar and causes the increase of the Aβ
proto-fibrillars clearance and/or leads to neutralize toxic effects on neurons in the brain [53, 54].

**GSK933776**

GSK933776 is a humanized immunoglobulin G1 monoclonal antibody (IgG1) that acts against AB n-terminal. Its Fc domain has been mutated to reduce the risk of vasogenic edema [53].

**SAR228810**

SAR228810 is a humanized monoclonal antibody that acts against proto-fibrillars and ABs with low molecular weight [53].

**BIB037/BART**

BIB037/BART is a human complete IgG1 monoclonal antibody that acts against insoluble fibrillar human AB [53].

**Immunotherapy against Tau**

Immunotherapy can also act as an approach to target Tau protein. In fact, it has been shown that the reduction of Tau sedimentation and the improvement of clearing of Tau oligomers and insoluble deposits can all be accomplished with immunotherapy [55].

In conclusion, based on reports from previous studies infectious disorders and metabolic disorders, including diabetes and metabolic syndrome and cancer had high rate of prevalence. For treatment of the large ranges of diseases, nanotechnology had noticeable role in medicine and manufacturing.

Different nanotechnology based strategies such as nanoparticles have important role in drug delivery and therapy. Indeed, the treatments for some prevalent disorders including cancer are chemotherapy and herbal based therapeutic agents. In this regards monoclonal antibodies are involved in the field of large numbers of different disorders.

Designing monoclonal antibody is a new and appropriate approach for different diseases treatment in different fields. This monoclonal antibodies evolution will be promising in those diseases that there is not have not any specific and definitive treatment for them right now. Monoclonal antibodies have been designed against different kinds of AB that their purposes are cleaning toxic ABs from brain, amyloid cascade inhibition, and preventing of neuronal degeneration and brain function. The results are very promising in relation to multiple sclerosis disease, too. It is essential to mention that A slight percentage of antibodies passes the blood brain barrier in normalsubj (≤0.1%) with a somewhat higher percentage in patients with AD (0.5–1.0%); thus, it may be beneficial to search ways to produce new drug for AD.

**References**

22. K. Yang, J. Belrose, C. H. Trepanier, G. Lei, M. F. Jackson,


This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.